Random anti-Mullerian hormone predicts ovarian response in women with high baseline follicle-stimulating hormone levels Anti-Mullerian hormone in poor responders in assisted reproductive treatment

Tarih
2012Yazar
Celik, HandanBildircin, Devran
Guven, Davut
Cetinkaya, Mehmet B.
Alper, Tayfun
Batuoglu, A. Sertac
Üst veri
Tüm öğe kaydını gösterÖzet
To evaluate the predictive value of random serum anti-Mullerian hormone (AMH) in the assessment of ovarian response in patients with diminished ovarian reserve (DOR; diagnosed after the observation of elevated baseline levels of early follicular follicle-stimulating hormone [FSH]) who were undergoing intracytoplasmic sperm injection-embryo transfer (ICSI-ET) and to compare the random serum AMH and baseline FSH levels in these patients for the prediction of poor ovarian response. Retrospective study. University hospital. One hundred and thirty-nine patients who were undergoing ICSI-ET cycles with early follicular FSH level > 9 IU/mL. None. Poor ovarian response in ICSI-ET cycles. For the identification of women at risk of cycle cancellation, an AMH cut-off level a parts per thousand currency sign1.2 ng/mL had 97.3 % sensitivity, 31.3 % specificity, 33.9 % positive predictive value, and 96.9 % negative predictive value in the women with high baseline FSH levels. An AMH cut-off level a parts per thousand yen1 ng/mL had a sensitivity of 58.7 % and specificity of 95.1 % for prediction of retrieval of 4 or more oocytes. By using a serum AMH cutoff level of 1.5 ng/mL, the ongoing pregnancies were predicted with 83.3 % sensitivity and 82.5 % specificity and yielded a positive predictive value of 31.2 % and a negative predictive value 98.1 %. Measurement of random serum AMH level is a useful tool in the prediction of ovarian response in patients with high serum early follicular FSH levels.
Kaynak
Journal of Assisted Reproduction and GeneticsCilt
29Sayı
8Koleksiyonlar
İlgili Öğeler
Başlık, yazar, küratör ve konuya göre gösterilen ilgili öğeler.
-
Treatment of chronic anovulation resistant to clomiphene citrate (CC) by using gonadotrophin-releasing hormone agonist (GnRH-a) ovarian suppression followed by recombinant follicle-stimulating hormone (r-hFSH) treatment (Suprecur, Puregon)
Koçak I.; Demirel C.; Aytaç R.; Üstün C.; Ünlü C. (2001)We performed a prospective study to assess the effects of a starting dose of 50 units of recombinant follicle stimulating hormone (Puregon) during gonadotrophin-releasing hormone agonist therapy (Suprecur) on follicular ... -
Women's perception of the menopause and hormone treatment: barriers against hormone therapy
Sahin, N. H.; Bal, M. D.; Boga, N. M.; Gokdemirel, S.; Taspinar, A. (Taylor & Francis Ltd, 2011)Objectives To identify the mean age of menopause, menopausal symptoms, and perceptions of hormone therapy (HT) among women aged 20-64 years in Turkey. Methods The study was descriptive and cross-sectional. A total of 729 ... -
Teknik derin dalış ve engelli dalışında motivasyon ve stres faktörleri ile stres hormon değişimleri / Deniz Özyurt; Danışman Atilla Tekat
Özyurt, Deniz (Ondokuz Mayıs Üniversitesi, Sağlık Bilimleri Enstitüsü, 2008)…